Impact Factor
3.36
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.58
589 total citations
h5-index
25
h5 depth signal
Cited share
76.2%
189 of 248
Total citations
589
Citation footprint
Metric signal
2.79
External metric anchor
Self-citation
1.5%
9 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
368
India
253
Iran
213
Turkey
163
China
148
Citing Fields of Research
Liver & Colon Cancer
754
Oncology
689
Digestive Disorders
597
Abdominal Surgery
140
Musculoskeletal & Nerve Cancer
122
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,061
Articles tracked across the journal lifetime
Indexed publication set
248
189 cited publications
Last 12 months
284
23.7 publications/month
Open access share
22.2%
63 OA publications in the last year
Leading citing country
United States
368 citing publications
Leading citing field
Liver & Colon Cancer
754 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v38n1, 2007-
v38n1, 2007-
Research Focus & Classification
Indexed Subjects
Liver & Colon Cancer
Digestive Disorders
Oncology
Broad Categories
Gastroenterology
Neoplasms
Digestive Disorders
Liver & Colon Cancer
MeSH Descriptors
Gastrointestinal Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s12029-026-01620-w
Open DOI
Neoadjuvant Therapy for Gastric Adenocarcinoma with Signet Ring Cells: A Systematic Review and Meta-Analysis
02
03
DOI 10.1007/s12029-026-01608-6
Open DOI
A Meta-Analysis on Outcomes of Zanidatamab Plus Chemotherapy in Patients with Advanced HER2-positive Gastroesophageal Adenocarcinoma
Background: Zanidatamab is a novel HER2-targeted antibody that binds to two non-overlapping extracellular domains of the HER2 receptor. Early-phase trials have shown clinical benefit of first-line Zanidatamab in patients with advanced HE...
04
DOI 10.1007/s12029-026-01619-3
Open DOI
Correspondence: Interpreting Hazard Ratios in Meta-Analyses on ctDNA in Colorectal Cancer
05
06
07
08
DOI 10.1007/s12029-026-01610-y
Open DOI
Fibrolamellar Carcinoma in the Molecular Era: From DNAJB1::PRKACA Biology to Precision Therapeutic Strategies
09
DOI 10.1007/s12029-026-01612-w
Open DOI
Correspondence: Cachexia-Related Status in Advanced Gastric Cancer: Marker of Progression or Driver of Prognosis?
10
Bibliographical & Catalog Notes
Description based on first issue; title from cover.
Also issued online.